Phase 4 N=76 "The Once A Day Protease Inhibitor Regimens"
HIV Infections
Primary: Proportion of Patient With Viral Load Less Than 400 Copies/mL — 89; 73 percentage
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=47 A Phase II Trial of Afatinib(BIBW 2992) in Third-line Treatment for Patients With Stage IIIB/IV Adenocarcinoma of the Lung Harbouring Wild-type Epidermal Growth Factor Receptor[EGFR]
Carcinoma, Non-Small-Cell Lung
Primary: Percentage of Participants With Best Objective Response — 0 Percentage of participants
Phase 1 N=19 The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer
Carcinoma · Non-Small-Cell Lung Carcinoma · Head and Neck Neoplasms
Primary: Change From Baseline in Standardised Uptake Value (SUVmax) as Measured by 2-[F-18]-Fluoro-2-deoxy-D-glucose Positron Emission Tomography (FDG-PET) — -18.386 Percentage…
Phase 2 N=14 A Study on the Biobehavioral Mechanisms of Baclofen and Alcohol Drinking
Alcoholism
Primary: Alcohol Urge — 22.5; 19.4 units on a scale
Phase 2 N=185 Evaluating Neuroprotection in Aneurysm Coiling Therapy
Stroke
Primary: Volume of New FLAIR Lesions(MRI) — 915; 477 mm^3 — p=0.445
N/A N=673 A Study to Assess Whether PDE5 Inhibitors Increase the Chance of Triggering the Onset of Acute NAION
Optic Neuropathy, Ischemic
Primary: Number of Days Exposed to PDE5i During 1-Day Case Window and 29 1-Day Control Windows Among Participants Adjudicated as Definite NAION Cases — 14; 248 exposed days…
Phase 4 N=21 Treatment of Acute Hepatitis C Virus in HIV Co-Infection
Hepatitis C · Human Immunodeficiency Virus · HIV Infections
Primary: Sustained Virologic Response (SVR) — 62 percentage of participants
Phase 2 N=15 A Transiliac Crest Bone Histology and Histomorphometry Study in Postmenopausal Women With Low Bone Mass or Osteoporosis Previously Treated With Denosumab
Low Bone Mass · Low Bone Mineral Density · Osteoporosis
Primary: Number of Participants With Normal/Abnormal Bone Histology — 15; 15; 15; 0 Participants
Phase 1 N=35 Influence of Mild and Moderate Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of Various Doses of Afatinib
Liver Diseases · Healthy
Primary: Area Under Curve From 0 to Infinity (AUC0-infinity) — 886; 552; 934; 956 ng*h/mL — p=0.1998
Phase 1 N=47 Study to Determine the Maximum Tolerated Dose of BIBW 2992 (Afatinib) When Combined With Cisplatin/Paclitaxel or Cisplatin/5-FU in Patients With Advanced Solid Tumours
Neoplasms
Primary: Number of Participants With Dose Limiting Toxicities (DLT) in the First Cycle for the Determination of the Maximum Tolerated Dose (MTD) — 0; 0; 2; 2 Participants
Phase 3 N=75 Medtronic Concomitant Utilization of Radio Frequency for Atrial Fibrillation CURE-AF/Persistent
Atrial Fibrillation
Primary: Efficacy Endpoint: The Percent of Patients Off Class I or III Antiarrhythmic Drugs and Out of AF as Determined by 24 Hour Holter Recording at 9 Months — 42.6 percentage…
Phase 3 N=46 Effect of Vitamin D Treatment in Primary Hyperparathyroidism
Vitamin D Deficiency · Primary Hyperparathyroidism · Hypercalcemia
Primary: Decrease in Preoperative P-PTH — -2.2; 0.2 pmol/l
Phase 2 N=23 Viral Therapy in Treating Patients With Metastatic Melanoma
Recurrent Melanoma · Stage IV Melanoma
Primary: Tumor Response — 0; 0 participants
Phase 2 N=31 Combination Drug Therapy Followed by Single Drug Steroid Free Therapy to Prevent Organ Rejection in Kidney Transplantation
Kidney Transplantation
Primary: The Rate of Allograft Rejection — 0; 0 participants
Phase 3 N=75 Concomitant Utilization of Radio Frequency Energy for Atrial Fibrillation (CURE-AF) Study
Atrial Fibrillation
Primary: Efficacy Endpoint: The Percent of Patients Off Class I and/or III Antiarrhythmic Drugs and Out of Atrial Fibrillation as Determined by 24 Hour Holter Recording Conducted…